- Home
- PHAR vs HKD Comparison
PHAR vs HKD Comparison
Compare PHAR & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- HKD
- Stock Information
- Founded
- PHAR 1988
- HKD 2003
- Country
- PHAR Netherlands
- HKD France
- Employees
- PHAR N/A
- HKD N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- HKD Finance: Consumer Services
- Sector
- PHAR Health Care
- HKD Finance
- Exchange
- PHAR Nasdaq
- HKD Nasdaq
- Market Cap
- PHAR 731.1M
- HKD 656.8M
- IPO Year
- PHAR N/A
- HKD 2022
- Fundamental
- Price
- PHAR $10.42
- HKD $1.77
- Analyst Decision
- PHAR Strong Buy
- HKD
- Analyst Count
- PHAR 3
- HKD 0
- Target Price
- PHAR $30.00
- HKD N/A
- AVG Volume (30 Days)
- PHAR 3.5K
- HKD 250.3K
- Earning Date
- PHAR 07-31-2025
- HKD 01-01-0001
- Dividend Yield
- PHAR N/A
- HKD N/A
- EPS Growth
- PHAR N/A
- HKD 9.93
- EPS
- PHAR N/A
- HKD 0.23
- Revenue
- PHAR $320,708,000.00
- HKD $20,445,000.00
- Revenue This Year
- PHAR $13.31
- HKD N/A
- Revenue Next Year
- PHAR $7.68
- HKD N/A
- P/E Ratio
- PHAR N/A
- HKD $7.68
- Revenue Growth
- PHAR 24.13
- HKD N/A
- 52 Week Low
- PHAR $6.65
- HKD $1.65
- 52 Week High
- PHAR $12.61
- HKD $5.80
- Technical
- Relative Strength Index (RSI)
- PHAR 48.06
- HKD 44.88
- Support Level
- PHAR $9.99
- HKD $1.72
- Resistance Level
- PHAR $10.49
- HKD $1.84
- Average True Range (ATR)
- PHAR 0.33
- HKD 0.07
- MACD
- PHAR -0.11
- HKD 0.01
- Stochastic Oscillator
- PHAR 29.19
- HKD 48.33
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.